Chromosome 9p and 10q Losses Predict Unfavorable Outcome in Low-grade Gliomas

Overview

Journal Neuro Oncol

Publisher Oxford University Press

Specialties Neurology
Oncology

Date 2010 Feb 13

PMID 20150361

Citations 13

Authors

Caroline Houillier

Karima Mokhtari

Catherine Carpentier

Emmanuelle Criniere

Yannick Marie

Audrey Rousseau

Gentian Kaloshi

Caroline Dehais

Julien Laffaire

Florence Laigle-Donadey

Khe Hoang-Xuan

Marc Sanson

Jean-Yves Delattre

Affiliations

Soon will be listed here.

Abstract

The loss of chromosomes 1p-19q is the only prognostic molecular alteration identified in low-grade gliomas (LGGs) to date. Search for loss of heterozygosity (LOH) on chromosomes 1p, 9p, 10q, and 19q was performed in a series of 231 LGGs. Loss of chromosomes 1p-19q was strongly correlated with prolonged progression-free survival (PFS) and overall survival (OS) in univariate and multivariate analyses. LOH on 9p and 10q were associated with shortened PFS (P = .01 and .03, respectively) on univariate analysis. On multivariate analysis, LOH on 9p remained significant for PFS (P = .05), whereas LOH on 10q had a significant effect on OS (P = .02). Search for LOH 9p and 10q appears to be a useful complement to analysis of chromosomes 1p-19q in LGGs.

Citing Articles

Adolescent and young adult glioma: systematic review of demographic, disease, and treatment influences on survival.

Malhotra A, Karthikeyan V, Zabih V, Landry A, Bennett J, Bartels U Neurooncol Adv. 2022; 4(1):vdac168.

PMID: 36479061 PMC: 9721387. DOI: 10.1093/noajnl/vdac168.

The Role of Neurodevelopmental Pathways in Brain Tumors.

Curry R, Glasgow S Front Cell Dev Biol. 2021; 9:659055.

PMID: 34012965 PMC: 8127784. DOI: 10.3389/fcell.2021.659055.

Transcription factors NFIA and NFIB induce cellular differentiation in high-grade astrocytoma.

Chen K, Bridges C, Lynton Z, Lim J, Stringer B, Rajagopal R J Neurooncol. 2019; 146(1):41-53.

PMID: 31760595 DOI: 10.1007/s11060-019-03352-3.

Integrated systems-genetic analyses reveal a network target for delaying glioma progression.

Laaniste L, Srivastava P, Stylianou J, Syed N, Cases-Cunillera S, Shkura K Ann Clin Transl Neurol. 2019; 6(9):1616-1638.

PMID: 31420939 PMC: 6764637. DOI: 10.1002/acn3.50850.

Machine Learning Versus Logistic Regression Methods for 2-Year Mortality Prognostication in a Small, Heterogeneous Glioma Database.

Panesar S, Dsouza R, Yeh F, Fernandez-Miranda J World Neurosurg X. 2019; 2:100012.

PMID: 31218287 PMC: 6581022. DOI: 10.1016/j.wnsx.2019.100012.

References

Hulsebos T, Oskam N, Troost D, Leenstra S, Bijleveld E . Dynamics of genetic alterations associated with glioma recurrence. Genes Chromosomes Cancer. 1998; 23(2):153-8. View

Claus E, Black P . Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973-2001. Cancer. 2006; 106(6):1358-63. DOI: 10.1002/cncr.21733. View

Shaw E, Arusell R, Scheithauer B, OFallon J, ONeill B, Dinapoli R . Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol. 2002; 20(9):2267-76. DOI: 10.1200/JCO.2002.09.126. View

Coons S, Johnson P, Scheithauer B, Yates A, Pearl D . Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer. 1997; 79(7):1381-93. DOI: 10.1002/(sici)1097-0142(19970401)79:7<1381::aid-cncr16>3.0.co;2-w. View

Iwamoto F, Nicolardi L, Demopoulos A, Barbashina V, Salazar P, Rosenblum M . Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. J Neurooncol. 2008; 88(3):293-8. DOI: 10.1007/s11060-008-9563-z. View

McCormack B, Miller D, BUDZILOVICH G, Voorhees G, Ransohoff J . Treatment and survival of low-grade astrocytoma in adults--1977-1988. Neurosurgery. 1992; 31(4):636-42; discussion 642. DOI: 10.1227/00006123-199210000-00004. View

Thiessen B, Maguire J, McNeil K, Huntsman D, Martin M, Horsman D . Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity. J Neurooncol. 2003; 64(3):271-8. DOI: 10.1023/a:1025689004046. View

Kujas M, Lejeune J, Benouaich-Amiel A, Criniere E, Laigle-Donadey F, Marie Y . Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas. Ann Neurol. 2005; 58(2):322-6. DOI: 10.1002/ana.20543. View

Jenkins R, Blair H, Ballman K, Giannini C, Arusell R, Law M . A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006; 66(20):9852-61. DOI: 10.1158/0008-5472.CAN-06-1796. View

10.

Dehais C, Laigle-Donadey F, Marie Y, Kujas M, Lejeune J, Benouaich-Amiel A . Prognostic stratification of patients with anaplastic gliomas according to genetic profile. Cancer. 2006; 107(8):1891-7. DOI: 10.1002/cncr.22211. View

11.

Trost D, Ehrler M, Fimmers R, Felsberg J, Sabel M, Kirsch L . Identification of genomic aberrations associated with shorter overall survival in patients with oligodendroglial tumors. Int J Cancer. 2007; 120(11):2368-76. DOI: 10.1002/ijc.22574. View

12.

He J, Mokhtari K, Sanson M, Marie Y, Kujas M, Huguet S . Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol. 2001; 60(9):863-71. DOI: 10.1093/jnen/60.9.863. View

13.

Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P . Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002; 20(8):2076-84. DOI: 10.1200/JCO.2002.08.121. View

14.

Weber R, Sabel M, Reifenberger J, Sommer C, Oberstrass J, Reifenberger G . Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization. Oncogene. 1996; 13(5):983-94. View

15.

Houillier C, Lejeune J, Benouaich-Amiel A, Laigle-Donadey F, Criniere E, Mokhtari K . Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer. 2006; 106(10):2218-23. DOI: 10.1002/cncr.21819. View

16.

Kitange G, Misra A, Law M, Passe S, Kollmeyer T, Maurer M . Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas. Genes Chromosomes Cancer. 2004; 42(1):68-77. DOI: 10.1002/gcc.20108. View

17.

Hulsebos T, Troost D, Leenstra S . Molecular-genetic characterisation of gliomas that recur as same grade or higher grade tumours. J Neurol Neurosurg Psychiatry. 2004; 75(5):723-6. PMC: 1763568. DOI: 10.1136/jnnp.2003.025031. View

18.

Deimling A, Louis D, Wiestler O . Molecular pathways in the formation of gliomas. Glia. 1995; 15(3):328-38. DOI: 10.1002/glia.440150312. View

19.

Mariani L, Deiana G, Vassella E, Fathi A, Murtin C, Arnold M . Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy. J Clin Oncol. 2006; 24(29):4758-63. DOI: 10.1200/JCO.2006.05.9238. View

20.

Idbaih A, Carvalho Silva R, Criniere E, Marie Y, Carpentier C, Boisselier B . Genomic changes in progression of low-grade gliomas. J Neurooncol. 2008; 90(2):133-40. DOI: 10.1007/s11060-008-9644-z. View